June 25, 2012
Our brief article describing the SAR study around TUG-469 and TAK-875, leading to the identification of an FFA1 agonist more potent and less lipophilic than both of these, is accepted by J. Med. Chem.
June 18-19, 2012
The first general FFARMED project meeting takes place in Copenhagen.
April 24, 2012
Our paper describing the first potent and selective GPR120 agonist is accepted by the Journal of Medicinal Chemistry.
March 25-29, 2012
The FFARMED project is represented by three posters and one oral presentation at the 243rd National Meeting of the American Chemical Society in San Diego, California.
February 27, 2012
A paper in Lancet describes the highly encouraging results from phase 2 clinical trials for treatment of type 2 diabetes with Takeda's selective FFA1 agonist TAK-875.
February 18, 2012
A new Nature paper reports that dysfunctional GPR120 leads to obesity in both mouse and human.
February 8, 2012
The first FFARMED steering group meeting takes place in Odense.